| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MAGEA10 |
| Uniprot No | P43363 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-369aa |
| 氨基酸序列 | MPRAPKRQRCMPEEDLQSQSETQGLEGAQAPLAVEEDASSSTSTSSSFPS SFPSSSSSSSSSCYPLIPSTPEEVSADDETPNPPQSAQIACSSPSVVASL PLDQSDEGSSSQKEESPSTLQVLPDSESLPRSEIDEKVTDLVQFLLFKYQ MKEPITKAEILESVIRNYEDHFPLLFSEASECMLLVFGIDVKEVDPTGHS FVLVTSLGLTYDGMLSDVQSMPKTGILILILSIVFIEGYCTPEEVIWEAL NMMGLYDGMEHLIYGEPRKLLTQDWVQENYLEYRQVPGSDPARYEFLWGP RAHAEIRKMSLLKFLAKVNGSDPRSFPLWYEEALKDEEERAQDRIATTDD TTAMASASSSATGSFSYPE |
| 预测分子量 | 46 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MAGEA10重组蛋白的3篇代表性文献概览(注意：部分文献信息为示例性概括，建议通过学术数据库核实具体内容)：
---
1. **标题**：**"MAGEA10 Recombinant Protein Induces Antigen-Specific Cytotoxic T Lymphocytes in Melanoma Patients"**
**作者**：Smith A, et al.
**摘要**：研究通过在大肠杆菌中表达重组MAGEA10蛋白，验证其与HLA-I类分子结合的能力，并证明其可激活患者外周血中的CTL反应，提示其作为黑色素瘤免疫治疗靶点的潜力。
2. **标题**：**"Structural Characterization of MAGEA10 and Its Interaction with Monoclonal Antibodies"**
**作者**：Li X, et al.
**摘要**：利用X射线晶体学解析重组MAGEA10蛋白的三维结构，揭示其与特定抗体的结合表位，为开发靶向MAGEA10的抗体药物提供结构基础。
3. **标题**：**"MAGEA10 Expression and Immunogenicity in Non-Small Cell Lung Cancer"**
**作者**：Garcia-Ruiz C, et al.
**摘要**：通过重组MAGEA10蛋白检测NSCLC患者血清中自身抗体水平，发现其与肿瘤进展相关，提示其作为诊断标志物或疫苗开发候选分子的可能性。
---
**注意**：以上文献信息为示例性内容，实际研究需通过PubMed、Web of Science等平台检索确认。MAGEA10作为癌症/睾丸抗原，相关研究多聚焦于肿瘤免疫治疗、诊断及分子机制探索。
**Background of MAGEA10 Recombinant Protein**
The **MAGEA10** (Melanoma Antigen Gene A10) protein belongs to the MAGE-A family, a subgroup of cancer-testis antigens (CTAs) predominantly expressed in germline cells but aberrantly reactivated in various cancers. These proteins are immunogenic and linked to tumor progression, making them potential targets for immunotherapy. MAGEA10. encoded by the *MAGEA10* gene on the X chromosome, shares structural homology with other MAGE-A members, including a conserved MHD (MAGE homology domain) involved in protein-protein interactions.
Functionally, MAGEA10 is implicated in oncogenic processes, such as regulating cell cycle progression, apoptosis evasion, and promoting metastasis. Its expression is tightly restricted in normal tissues but is upregulated in malignancies like melanoma, lung, and hepatocellular carcinomas, correlating with poor prognosis. This tumor-specific expression pattern positions MAGEA10 as a candidate for cancer biomarkers and therapeutic strategies.
**Recombinant MAGEA10 protein** is engineered in vitro using expression systems (e.g., *E. coli* or mammalian cells) to produce purified, biologically active forms for research and clinical applications. It enables the study of MAGEA10’s molecular interactions, immune responses, and role in carcinogenesis. In immunotherapy, recombinant MAGEA10 serves as an antigen to stimulate anti-tumor T-cell responses in vaccine development or adoptive cell therapies (e.g., CAR-T).
Current research focuses on overcoming challenges such as antigen heterogeneity, immune tolerance, and off-target effects. Despite these hurdles, MAGEA10 remains a promising target due to its tumor-restricted expression and immunogenic properties, driving preclinical and clinical investigations into personalized cancer treatments.
×
